<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00330967</url>
  </required_header>
  <id_info>
    <org_study_id>ENDA-029-05F</org_study_id>
    <nct_id>NCT00330967</nct_id>
  </id_info>
  <brief_title>Mechanisms of Insulin Resistance in Humans</brief_title>
  <official_title>Mechanisms of Insulin Resistance in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Objectives of the study are to: (1)compare the inflammatory response and insulin
      resistance in skeletal muscles during a systemic infusion of lipid with that during a local
      infusion of lipid into the femoral artery. which would cause minimal or no systemic
      hyperlipidemia but local plasma free fatty acid (FFA) concentrations similar to those during
      the systemic lipid infusion, and (2) determine the inflammatory response and insulin
      resistance in skeletal muscle during an infusion of lipid into the femoral artery as
      described above after NF-KB inhibition by high dose salicylate treatment in humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Insulin resistance in skeletal muscle is a characteristic abnormality in obesity and the
      metabolic syndrome and a major factor responsible for the development of type 2 diabetes.
      Although the mechanisms responsible for muscle insulin resistance are largely unclear, lipid
      oversupply is an important factor. Among numerous potential mechanisms whereby lipid
      oversupply may cause muscle insulin resistance, current evidence points towards inflammation
      as being critical. Recent studies in animals, however, indicate that the inflammatory
      response in skeletal muscles may require the presence of circulating pro-inflammatory factors
      suggesting that the inflammation induced insulin resistance in skeletal muscles may be a
      secondary event. More specifically, activation of Nuclear Factor-Kappa B(NF-kB), and
      inflammatory master switch that drives the production of numerous pro-inflammatory cytokines
      in fat and liver, has been implicated in causing insulin resistance in skeletal muscles by
      increasing circulating pro-inflammatory cytokines. In contrast, animal studies have found
      that activation of NF-KB directly in skeletal muscles has no or little effect on its insulin
      sensitivity but does produce other abnormalities such as increased proteasome activity. The
      study shall therefore be undertaken to determine to what extent lipid-induced inflammation
      and insulin resistance in skeletal muscles requires the presence of circulating
      proinflammatory factors in humans.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Signaling With Lipid Infusion</measure>
    <time_frame>4 h</time_frame>
    <description>IRS-1 expression in response to femoral lipid infusion in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blot bands, normalized to a housekeeping protein, GAPDH, in control and treated groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phos-p38 MAPK Expression With Femoral Lipid and Insulin Infusions</measure>
    <time_frame>4 h</time_frame>
    <description>Phosphorylation of p38 MAPK in response to femoral lipid and insulin infusions. phospho-p38 MAPK expression in response to femoral lipid infusion in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>p38 MAPK Expression With Femoral Lipid and Insulin Infusions</measure>
    <time_frame>4 h</time_frame>
    <description>p38 MAPK expression in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phospho-ERK MAPK Expression With Femoral Lipid and Insulin Infusions</measure>
    <time_frame>4 h</time_frame>
    <description>Phosphorylation of ERK MAPK in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ERK MAPK Expression With Femoral Lipid and Insulin Infusions</measure>
    <time_frame>4 h</time_frame>
    <description>ERK MAPK expression in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phospho-JNK MAPK Expression With Femoral Lipid and Insulin Infusions</measure>
    <time_frame>4 h</time_frame>
    <description>Phosphorylation of JNK MAPK in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>JNK MAPK Expression With Femoral Lipid and Insulin Infusions</measure>
    <time_frame>4 h</time_frame>
    <description>JNK MAPK expression in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Inflammation</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>healthy subjects different from group 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20% Intralipid</intervention_name>
    <description>lipid infusion</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples, muscle biopsies
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        healthy subjects
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  two groups of 16 healthy subjects

        Exclusion Criteria:

          -  diabetes or impaired glucose tolerance

          -  peripheral vascular disease

          -  pulmonary disease

          -  clinically significant hepatic or renal disease

          -  triglycerides &gt;200mg/dl

          -  anemia

          -  abnormal PT, PTT or INR

          -  pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles C Oh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Phoenix VA Health Care System Carl T. Hayden VA Medical Center, Phoenix, AZ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix VA Health Care System Carl T. Hayden VA Medical Center, Phoenix, AZ</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2006</study_first_submitted>
  <study_first_submitted_qc>May 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2006</study_first_posted>
  <results_first_submitted>January 22, 2015</results_first_submitted>
  <results_first_submitted_qc>March 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2015</results_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fat Emulsions, Intravenous</keyword>
  <keyword>Free Fatty Acids</keyword>
  <keyword>Glucose Clamp Technique</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Insulin Resistance</keyword>
  <keyword>Muscle, Skeletal</keyword>
  <keyword>NF-Kappa B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Systemic Intralipid infusion subjects
20% Intralipid: lipid infusion</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>Femoral arterial Intralipid infusion subjects
20% Intralipid: lipid infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Systemic Intralipid infusion subjects
20% Intralipid: lipid infusion</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Femoral Intralipid infusion subjects
20% Intralipid: lipid infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="47.65" spread="11.43"/>
                    <measurement group_id="B3" value="47.65" spread="11.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Signaling With Lipid Infusion</title>
        <description>IRS-1 expression in response to femoral lipid infusion in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blot bands, normalized to a housekeeping protein, GAPDH, in control and treated groups.</description>
        <time_frame>4 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Femoral Intralipid infusion subjects
20% Intralipid: lipid infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Signaling With Lipid Infusion</title>
          <description>IRS-1 expression in response to femoral lipid infusion in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blot bands, normalized to a housekeeping protein, GAPDH, in control and treated groups.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IRS-1 Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4334" spread="0.2199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IRS-1 Basal Lipid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7276" spread="0.0173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IRS-1 Insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5264" spread="0.3810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IRS-1 Insulin Lipid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3534" spread="0.1391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phos-p38 MAPK Expression With Femoral Lipid and Insulin Infusions</title>
        <description>Phosphorylation of p38 MAPK in response to femoral lipid and insulin infusions. phospho-p38 MAPK expression in response to femoral lipid infusion in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
        <time_frame>4 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Femoral Intralipid infusion group</description>
          </group>
        </group_list>
        <measure>
          <title>Phos-p38 MAPK Expression With Femoral Lipid and Insulin Infusions</title>
          <description>Phosphorylation of p38 MAPK in response to femoral lipid and insulin infusions. phospho-p38 MAPK expression in response to femoral lipid infusion in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phos-p38 MAPK Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000394" spread="0.000164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phos-p38 MAPK Basal Lipid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001271" spread="0.001013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phos-p38 MAPK Insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000337" spread="0.000140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phos-p38 MAPK Insulin Lipid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000270" spread="0.000049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>p38 MAPK Expression With Femoral Lipid and Insulin Infusions</title>
        <description>p38 MAPK expression in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
        <time_frame>4 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Femoral Intralipid infusion group</description>
          </group>
        </group_list>
        <measure>
          <title>p38 MAPK Expression With Femoral Lipid and Insulin Infusions</title>
          <description>p38 MAPK expression in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>p38 MAPK Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000455" spread="0.0000088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p38 MAPK Basal Lipid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001291" spread="0.0008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p38 MAPK Insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000502" spread="0.000337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p38 MAPK Insulin Lipid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000377" spread="0.0000903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phospho-ERK MAPK Expression With Femoral Lipid and Insulin Infusions</title>
        <description>Phosphorylation of ERK MAPK in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
        <time_frame>4 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Femoral Intralipid infusion group</description>
          </group>
        </group_list>
        <measure>
          <title>Phospho-ERK MAPK Expression With Femoral Lipid and Insulin Infusions</title>
          <description>Phosphorylation of ERK MAPK in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phos-ERK MAPK Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000091" spread="0.0000378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phos-ERK MAPK Basal Lipid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000108" spread="0.0000366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phos-ERK MAPK Insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000096" spread="0.0000103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phos-ERK MAPK Insulin Lipid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000092" spread="0.0000070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ERK MAPK Expression With Femoral Lipid and Insulin Infusions</title>
        <description>ERK MAPK expression in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
        <time_frame>4 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Femoral Intralipid infusion group</description>
          </group>
        </group_list>
        <measure>
          <title>ERK MAPK Expression With Femoral Lipid and Insulin Infusions</title>
          <description>ERK MAPK expression in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ERK MAPK Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000103" spread="0.0000722"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERK MAPK Basal Lipid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000158" spread="0.0000826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERK MAPK Insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000124" spread="0.0000237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ERK MAPK Insulin Lipid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000114" spread="0.0000017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phospho-JNK MAPK Expression With Femoral Lipid and Insulin Infusions</title>
        <description>Phosphorylation of JNK MAPK in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
        <time_frame>4 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Femoral Intralipid infusion group</description>
          </group>
        </group_list>
        <measure>
          <title>Phospho-JNK MAPK Expression With Femoral Lipid and Insulin Infusions</title>
          <description>Phosphorylation of JNK MAPK in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Phos-JNK MAPK Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00401" spread="0.002967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phos-JNK MAPK Basal Lipid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005888" spread="0.004952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phos-JNK MAPK Insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003756" spread="0.002537"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phos-JNK MAPK Insulin Lipid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00224" spread="0.001161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>JNK MAPK Expression With Femoral Lipid and Insulin Infusions</title>
        <description>JNK MAPK expression in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
        <time_frame>4 h</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Femoral Intralipid infusion group</description>
          </group>
        </group_list>
        <measure>
          <title>JNK MAPK Expression With Femoral Lipid and Insulin Infusions</title>
          <description>JNK MAPK expression in response to femoral lipid and insulin infusions in skeletal muscle. Relative protein expression was calculated by densitometry analysis of Western blots, normalized to a housekeeping protein, GAPDH, of control and treated groups.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>JNK MAPK Basal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001364" spread="0.00594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JNK MAPK Basal Lipid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002996" spread="0.002837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JNK MAPK Insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.002151" spread="0.002032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JNK MAPK Insulin Lipid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001783" spread="0.001883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Systemic Intralipid infusion group
20% Intralipid: lipid infusion</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Femoral Intralipid infusion group
20% Intralipid: lipid infusion</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <description>Right lower extremity edema following muscle biopsy.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study's original Principal Investigator left the VA prior to the completion of data acquisition and no further subjects were enrolled. The data entered were analyzed based solely on study files in the system.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Charles Oh</name_or_title>
      <organization>Phoenix VA Health Care System</organization>
      <phone>602-277-5551 ext 1-5127</phone>
      <email>charles.oh@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

